Metraipolis › archive › dc_71c63cbd44e6
Early real-life outcomes of dupilumab and mepolizumab in patients with uncontrolled primary diffuse type 2 chronic rhinosinusitis — Europe PMC PMID:41109883
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41109883
- DOI
- 10.1007/s00405-[numero omesso]-x
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T05:20:30.672Z
- SHA-256 of the archived text
d75548a5a9060a3866b5b6c04989c29f48b353300270cf503fccefe2feda68e5- Stable URL of this page
https://metraipolis.com/documento/dc_71c63cbd44e6
How to cite
Early real-life outcomes of dupilumab and mepolizumab in patients with uncontrolled primary diffuse type 2 chronic rhinosinusitis — Europe PMC PMID:41109883 — Europe PMC (en), https://europepmc.org/article/MED/41109883 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_71c63cbd44e6 (Metraipolis archive dc_71c63cbd44e6, sha256 d75548a5a9060a3866b5b6c04989c29f48b353300270cf503fccefe2feda68e5)
BibTeX
@misc{dc71c63cbd44e6,
title = {Early real-life outcomes of dupilumab and mepolizumab in patients with uncontrolled primary diffuse type 2 chronic rhinosinusitis — Europe PMC PMID:41109883},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41109883},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_71c63cbd44e6; sha256 d75548a5a9060a3866b5b6c04989c29f48b353300270cf503fccefe2feda68e5},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41109883. Agents can read the archived copy with the MCP tool read_document.